Novel pharmacodynamic biomarkers for MYCN protein and PI3K/AKT/mTOR pathway signaling in children with neuroblastoma

Por Smith, Jennifer R., Moreno, Lucas, Heaton, Simon P., Chesler, Louis, Pearson, Andrew D.J., Garrett, Michelle D.
Publicado no Mol Oncol (2015)

Preclinical pharmacology, antitumor activity and development of pharmacodynamic markers for the novel, potent AKT inhibitor CCT128930

Por Yap, Timothy A., Walton, Mike I., Hunter, Lisa-Jane K., Valenti, Melanie, de Haven Brandon, Alexis, Eve, Paul D., Ruddle, Ruth, Heaton, Simon P., Henley, Alan, Pickard, Lisa, Vijayaraghavan, Gowri, Caldwell, John J., Thompson, Neil T., Aherne, Wynne, Raynaud, Florence I., Eccles, Suzanne A., Workman, Paul, Collins, Ian, Garrett, Michelle D.
Publicado no Mol Cancer Ther (2010)

Interrogating two schedules of the AKT inhibitor MK-2206 in patients with advanced solid tumors incorporating novel pharmacodynamic and functional imaging biomarkers

Por Yap, Timothy A., Yan, Li, Patnaik, Amita, Tunariu, Nina, Biondo, Andrea, Fearen, Ivy, Papadopoulos, Kyriakos P., Olmos, David, Baird, Richard, Delgado, Liliana, Tetteh, Ernestina, Beckman, Robert A., Lupinacci, Lisa, Riisnaes, Ruth, Decordova, Shaun, Heaton, Simon P., Swales, Karen, deSouza, Nandita M, Leach, Martin O., Garrett, Michelle D., Sullivan, Daniel M., de Bono, Johann S., Tolcher, Anthony W.
Publicado no Clin Cancer Res (2014)